Destruction of the rainforest increased by 9.5% compared to the previous 12 months, new data shows.
CHANDLER, Ariz., Nov. 30, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Microchip Technology Inc. (NASDAQ:MCHP), please note that, in paragraph one, the time of the company's presentation at the 2020 Wells Fargo TMT Summit should be 12:00 p.m. (Eastern Time). The corrected release follows:(NASDAQ:MCHP) – Microchip Technology Incorporated, a leading provider of smart, connected and secure embedded control solutions, announced today that the Company will present at the 2020 Wells Fargo TMT Summit on Wednesday, December 2, 2020, at 12:00 p.m. (Eastern Time). Presenting for the Company will be Mr. Steve Sanghi, Chief Executive Officer, and Mr. Eric Bjornholt, Senior Vice President and Chief Financial Officer. A live webcast of the presentation will be made available by Wells, and can be accessed on the Microchip website at www.microchip.com. Any forward looking statements made during the presentation are qualified in their entirety by the discussion of risks set forth in the Company's Securities and Exchange Commission filings. Copies of SEC filings can be obtained for free at the SEC's website (www.sec.gov) or from commercial document retrieval services.Microchip Technology Incorporated is a leading provider of smart, connected and secure embedded control solutions. Its easy-to-use development tools and comprehensive product portfolio enable customers to create optimal designs, which reduce risk while lowering total system cost and time to market. The company's solutions serve more than 120,000 customers across the industrial, automotive, consumer, aerospace and defense, communications and computing markets. Headquartered in Chandler, Arizona, Microchip offers outstanding technical support along with dependable delivery and quality. For more information, visit the Microchip website at www.microchip.com.Note: The Microchip name and logo are registered trademarks of Microchip Technology Inc. in the USA and other countries.INVESTOR RELATIONS CONTACT:Deborah Wussler ……… (480) 792-7373
Oak Street Health Announces Secondary Offering
Goldman Sachs Asset Management ("GSAM") will host a conference call for the Goldman Sachs MLP and Energy Renaissance Fund (NYSE: GER) on December 3rd, 2020 at 4:15 PM EST. The call will feature Kyri Loupis, Head of the Energy Infrastructure and Renewables team at GSAM, along with Portfolio Managers Ganesh Jois and Matthew Cooper. The call will briefly cover the market environment for the U.S. energy sector and provide an update on the closed-end fund investment strategy.
* Pre-clinical studies demonstrate potential of FT-104, its novel psychedelic molecule, as preferable option for psychedelic therapies, with comparable potency to psilocybin and shorter duration * 4 Field Trip Health centers are in operation, with Amsterdam and newly announced locations in Atlanta, GA and Houston, TX under construction * Digital applications Trip and Portal providing people with new tools for tele-therapy * Strong cash position of $14.0M to advance development of FT-104 and continue expansion of Field Trip Health Centers in North America and EuropeTORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (CSE: FTRP) (OTCBB: FTRPF) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, reported its second fiscal quarter results for the three and six months ended September 30, 2020. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars, unless otherwise specified.Key Highlights and Recent DevelopmentsDuring fiscal Q2 of 2021, Field Trip completed brokered and non-brokered private placements of an aggregate of 6,333,656 Class A shares in the capital of Field Trip, at a price of $2.00 per Field Trip Share, for aggregate gross proceeds of $12,667,312 (the “Financing”). Funds for these private placements were received in two tranches.As at September 30, 2020, Field Trip reported cash and cash equivalents of $14,042,025 which included $11,033448 gross proceeds from the first tranche of financing and $1,638,670 in other receivables, which primarily related to the second tranche funds from the Financing held in escrow and released in October.On October 1, 2020, Field Trip completed its previously announced going public transaction via a reverse takeover and began trading on the Canadian Securities Exchange (the “CSE”) under the stock symbol “FTRP”, as well as the OTCBB under the symbol “FTRPF”.With its strong cash position and recent listing, Field Trip is well-positioned to execute on its corporate strategy of building an integrated psychedelics company through its Field Trip Discovery and Field Trip Health Divisions. Field Trip Discovery’s focus includes: (i) continued development of FT-104, its first drug candidate, which is a novel synthetic psychedelic molecule; and (ii) advanced research and cultivation on psilocybin producing fungi at its research facility (the “Jamaica Facility”) at The University of West Indies (Mona) in Jamaica (“UWI”). Field Trip Health’s focus is on: (i) building out the clinical infrastructure needed to deliver psychedelic therapies at scale, with current and announced locations in Toronto, New York, Los Angeles, Chicago, Amsterdam, Atlanta, GA and Houston, TX; and (ii) developing digital tools to enhance and optimize the therapeutic experience in its Field Trip Health Centers and beyond, including Trip, its mobile application supporting consciousness expansion and Portal, its tools to support people participating in psychedelic therapies at Field Trip Health centers.FT-104FT-104 is a next-generation, synthetic psychedelic molecule whose design is, in part, based on classical serotonin 2A psychedelics. Patents are pending on FT-104’s structure, formulation and use in treating a variety of central nervous system disorders. Preliminary results for FT-104 demonstrate that FT-104 is similar in potency to psilocybin, but may provide a significantly shorter duration of psychedelic experience relative to psilocybin (in the range of two to four hours, which is approximately half the duration of psilocybin), making it a more convenient and potentially preferable option for psychedelic therapy. FT-104 is concurrently undergoing optimization and cGMP scale-up, as well as pre-clinical evaluation, both of which are expected to be completed by June 2021. Field Trip anticipates that FT-104 will enter into Phase 1, clinical trials in the second half of calendar year 2021.Psilocybin-producing Fungi Research and CultivationSince January 2020, Field Trip has successfully cultivated 24 varieties (from 13 different species) of psilocybin-producing fungi and truffles in a temporary facility at UWI’s Mona Campus, and in October 2020, Field Trip substantially completed construction of a 2,072 sq. ft. custom-built research and cultivation facility situated on UWI’s Mona campus. The purpose of the Jamaica Facility is to optimize the cultivation techniques and operating procedures for psilocybin-producing fungi and develop the analytical tools and techniques to ensure the safe use of domesticated species in psychedelic therapy in legal jurisdictions (states or countries) as markets for psilocybin-producing fungi continue to emerge. Field Trip anticipates utilizing such techniques and operating procedures at Field Trip Health’s Amsterdam location, as well expected operations in the State of Oregon, following the passage of Measure 109, which will effectively create the first legal market for psilocybin therapies in North America.In addition, Field Trip will seek to identify and quantify total tryptamine content, including psilocybin and other tryptamine analogues that may play a role in the psychedelic experience, and use this knowledge to optimize production of reproducible and well-characterized psychedelic botanical medicines. Further, any new substances identified during these efforts, may lead to promising new candidates for drug development.Field Trip Health CentersField Trip Health centers are primarily dedicated to the treatment of depression and other mental health conditions using proprietary protocols and settings within a framework of ketamine-assisted therapies but will offer therapies using other psychedelic molecules where and when permitted, including in The Netherlands and the State of Oregon.During the second fiscal quarter, following the successful opening of its Toronto location in March 2020, Field Trip opened Field Trip Health centers in the United States with locations in New York and Los Angeles. In October 2020, Field Trip completed construction at its Chicago location and expects to begin providing therapies to people in December.Field Trip also announced that it has entered into a lease to build a Field Trip Health center in Amsterdam, Netherlands, which will provide programs utilizing truffles containing psilocybin, which are legal in The Netherlands. Field Trip has also entered into two additional leases in Atlanta, GA and Houston, TX, respectively bringing the total number of Field Trip Health centers to a total of seven, ahead of schedule. The Field Trip Health center in Atlanta, GA will be a 5,189 sq. ft. facility located at Building 200, 750 Glenwood Avenue and is a part of the redevelopment of GlenCastle, which is Atlanta’s historic city stockade, stables and farm, that is being restored and repurposed into Atlanta’s most unique and creative office campus. The Houston center is a 4,600 sq. ft. facility located at Suite 4310 Westheimer Road, Suite 220 in Houston’s River Oaks neighborhood and will offer seven treatment rooms and a large group therapy room.Digital Teletherapy Tools: Trip and PortalDuring the second fiscal quarter, Field Trip also launched the Trip, a mobile app that provides users with a framework and tools to make the most of self-directed consciousness-expanding activities such as meditation and breathwork. Trip was released to users on Apple and Android platforms and has over 3,600 active users.Field Trip also launched Portal, a proprietary digital tool designed to complement its in-person therapeutic experience. Portal provides users with content, information, meditations, and synchronous and asynchronous communication tools for people in its psychedelic therapies and programs.Effects of COVID-19 Pandemic on OperationsOverall, Field Trip was not significantly affected by the COVID-19 pandemic. Although restrictions delayed construction on the New York and Los Angeles Field Trip Health centers, the delays were not significant and operations in its existing and planned Field Trip Health centers continue in earnest. As the COVID-19 pandemic has resulted in an estimated 300% increase in the incidence of depression in the US1, Field Trip anticipates that it will see an increase in expected long-term demand for its depression-related psychedelic therapies, particularly as case counts start to diminish in the future. However, Field Trip anticipates that financial results and operations for the forthcoming fiscal quarters may be negatively impacted by the COVID-19 pandemic as restrictions limit people’s ability to seek non-essential health services.Financial HighlightsFor the second fiscal quarter, Field Trip reported patient services revenues of $94,532 from its Toronto and New York Field Trip Health centers, which began continuous operations in June and August, respectively.Net loss for the second fiscal quarter of $3,932,444 was primarily due to general and administration expenses of $2,182,144, research and development expenses of $745,989, sales & marketing expenses of $268,475, patient services expenses of $232,114, occupancy costs of $111,877 and realized foreign exchange loss of $196,288. Net loss for the second fiscal quarter of 2020 of $514,643 was primarily due to general and administration expenses of $411,686, occupancy costs of $59,342 and sales and marketing expenses of $43,582.For the six months ended September 30, 2020, the Company reported patient services revenues of $118,131 from our Toronto and New York clinics. Net loss of $6,891,348 was primarily due to general and administration expenses of $3,536,064, research and development expenses of $1,480,991, sales & marketing expenses of $420,307, patient services expenses of $289,089, occupancy costs of $175,660 and realized foreign exchange loss of $591,010. Net loss for the period from April 2 (date of incorporation) to September 30, 2019 of $681,418 was primarily due to general and administration expenses of $564,331, occupancy costs of $73,472 and sales and marketing expenses of $43,582.Selected Consolidated Financial InformationThe following table sets forth selected financial information derived from the Company’s unaudited condensed interim financial statements for the three and six months ended September 30, 2020 and periods ended September 30, 2019, prepared in accordance with IAS 34 in a manner consistent with the Company’s annual audited financial statements. The following information should be read in conjunction with the financial statements and management’s discussion and analysis, which are available on the Company’s website at www.fieldtriphealth.com and under the Company’s SEDAR profile at www.sedar.com.(unaudited)3 months ended September 30, 2020 3 months ended September 30, 2019 6 months ended September 30, 2020 Period from April 2, 2019 (Date of Incorporation) to September 30, 2019 $ $ $ $ Revenue94,532 - 118,131 - Operating Expenses General and administration2,182,144 411,686 3,536,064 564,331 Occupancy costs111,877 59,342 175,660 73,472 Sales and marketing268,475 43,582 420,307 43,582 Research and development745,989 - 1,480,991 - Depreciation and amortization269,578 33 479,338 33 Patient services232,114 - 289,089 - 3,810,177 514,643 6,381,449 681,418 Other Income (Expenses) Finance expense(58,373) - (93,357) - Other expense(158,426) - (534,673) - Net Loss(3,932,444) (514,643) (6,891,348) (681,418) Net Loss per Share - Basic and Diluted(0.16) (0.08) (0.28) (0.11) Cash (including Restricted Cash)14,042,025 1,057,334 14,042,025 1,057,334 Other Receivables1,984,044 7,297 1,984,044 7,297 Total Assets22,468,694 1,175,561 22,468,694 1,175,561 Total Non-Current Financial Liabilities2,976,316 - 2,976,316 - Distributions- 13,596 - 13,596 Conference CallThe Company will conduct a conference call and webcast to review its results the following day, Tuesday, December 1, 2020 at 8:00 am ET. To access the call, please dial 1-877-407-9716 or 1-201-493-6779 and provide conference ID 13713475. A live webcast of the conference call can be accessed via the Events and Presentations section of the Field Trip Health Investor Relations website or via the following link: http://public.viavid.com/index.php?id=142525.For those unable to attend the live call, a telephonic replay will be available until December 15, 2020. To access the replay of the call dial 1-844-512-2921 or 1-412-317-6671 and provide conference ID 13713475. An archived copy of the webcast will be available on the Events and Presentations section of the Field Trip Health Investor Relations website after the conclusion of the call.______________________________________1Ettman CK, Abdalla SM, Cohen GH, Sampson L, Vivier PM, Galea S. Prevalence of Depression Symptoms in US Adults Before and During the COVID-19 Pandemic. JAMA Network Open. 2020;3(9):e2019686. doi:10.1001/jamanetworkopen.2020.19686About Field Trip Health Ltd.Field Trip is the global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics including psilocybin-producing fungi and our Field Trip Health division building centers for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale we help people, from those in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and heighten engagement with the world.Learn more at https://www.meetfieldtrip.com, https://www.fieldtriphealth.com and https://www.fieldtriphealth.nl.Follow us on Twitter and Instagram: @fieldtriphealthTo receive company updates about Field Trip and to be added to the email distribution list please sign up here.For further information, contact Ronan Levy, Executive Chairman, and a Director at Field Trip, at 1 (833) 833-1967.Cautionary Note Regarding Forward-Looking Information This release includes forward-looking information within the meaning of Canadian securities laws regarding Field Trip and its business, which may include, but are not limited to, statements with respect to the listing of the common shares of Field Trip on the Canadian Securities Exchange, and the timing of such events. Often but not always, forward-looking information can be identified by the use of words such as "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would" or "will" be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of Field Trip and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including risks regarding the COVID-19 epidemic, the medical clinic industry, market conditions, economic factors, management's ability to manage and to operate the business and the equity markets generally. Although Field Trip has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.The CSE has neither approved nor disapproved the contents of this news release.Media contacts: Paige Tatulli Autumn Communications 212-206-9780 firstname.lastname@example.org / email@example.comInvestor contacts: Elizabeth Barker KCSA Strategic Communications 212-896-1203 firstname.lastname@example.org SOURCE Field Trip Health Ltd.
There's a £250,000 difference between the highest and lowest paid star
The final day of the year’s best shopping event is here, and these are the best deals to shop now
* Leading Producer of Beverage and Food Can Stock for the N.A. Packaging Industry * Secular Demand Growth, Favorable Industry Supply/Demand Dynamics * Multi-Year Contracts and Strong Customer Relationships * Non-Cyclic Packaging Business Significantly Diversifies Product Portfolio * Immediately Accretive to Earnings with Positive Cash Flow FOOTHILL RANCH, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Kaiser Aluminum Corporation (NASDAQ:KALU), today announced that it has entered into a definitive agreement to purchase Alcoa Warrick LLC, containing all the assets of the Warrick Rolling Mill (“Warrick”), from Alcoa Corporation (“Alcoa”) for a purchase price of $670 million at an implied multiple of approximately seven times adjusted EBITDA as of the last twelve months ended September 30, 2020. Alcoa will retain ownership of the related smelting assets, power plant, and land. As part of the transaction, Kaiser Aluminum will enter into a market based molten aluminum supply agreement, and a long-term ground lease that includes provisions for utility services, and will have customary transition services.Warrick, located near Evansville, Indiana, has a leading position in the very attractive North American aluminum packaging industry. In the last twelve months, Warrick shipped over 675 million pounds of aluminum, of which approximately 60% was high-margin coated packaging products. The facility includes casting, significant hot and cold rolling capacity, and a range of finishing and coating lines, representing significant replacement value.“With Warrick’s solid market position, highly favorable market dynamics and a strong and culturally compatible management team, the acquisition provides us an opportunity to significantly enhance and diversify our portfolio,” said Keith A. Harvey, President and Chief Executive Officer.“The addition of a non-cyclic packaging business is highly complementary to our existing aerospace, automotive and general engineering cyclic end markets and provides excellent opportunities for long-term growth and synergy with our existing operations. Overall, the transaction is consistent with our longstanding strategy to acquire businesses that we understand at a price that creates long-term value for our shareholders, while continuing to adhere to our disciplined financial strategy for liquidity management and debt leverage,” stated Mr. Harvey.The transaction provides Kaiser Aluminum entry into the North American aluminum packaging industry, a growing end market driven by sustainability trends and the secular shift from plastic to aluminum in the packaging industry. Capacity for beverage and food can stock has shifted from packaging into other end markets resulting in favorable supply/demand dynamics. The addition of Warrick significantly increases Kaiser Aluminum’s scale and pro forma adjusted EBITDA. The transaction is expected to be immediately accretive to earnings and generate positive cash flow. Further financial details are included in the investor presentation posted on Kaiser Aluminum’s website at www.kaiseraluminum.com. Kaiser Aluminum intends to fund the purchase price with $587 million of existing cash on hand, and the assumption of $83 million of other post-employment benefits (OPEB) liabilities, subject to customary post-closing adjustments. The transaction is anticipated to close on or about March 31, 2021, subject to satisfaction of customary closing conditions and regulatory approvals.Jefferies LLC is acting as exclusive financial advisor to Kaiser Aluminum Corporation, McDermott Will & Emery LLP is acting as its legal advisor, and Deloitte & Touche is acting as diligence and transition advisor.Conference CallKaiser Aluminum Corporation will host a conference call on Tuesday, December 1, 2020, at 7:00am (Pacific Time); 9:00am (Central Time); 10:00am (Eastern Time), to further discuss the Alcoa Warrick LLC acquisition. To participate, the conference call can be directly accessed from the U.S. and Canada at (800) 697-5978, and accessed internationally at (630) 691-2750. A link to the simultaneous webcast can be accessed on the Company’s website at http://investors.kaiseraluminum.com/events.cfm. A copy of a presentation will be available for download prior to the call and an audio archive will be available on the Company’s website following the call.Company DescriptionKaiser Aluminum Corporation, headquartered in Foothill Ranch, Calif., is a leading producer of semi-fabricated specialty aluminum products, serving customers worldwide with highly-engineered solutions for aerospace and high-strength, custom automotive, general engineering, and other industrial applications. The Company’s North American facilities produce value-added sheet, plate, extrusions, rod, bar, tube, and wire products, adhering to traditions of quality, innovation, and service that have been key components of the culture since the Company was founded in 1946. The Company’s stock is included in the Russell 2000® index and the S&P Small Cap 600® index.Available InformationFor more information, please visit the Company’s website at www.kaiseraluminum.com. The website includes a section for investor relations under which the Company provides notifications of news or announcements regarding its financial performance, including Securities and Exchange Commission (SEC) filings, investor events, and earnings and other press releases. In addition, all Company filings submitted to the SEC are available through a link to the section of the SEC’s website at www.sec.gov, which includes: Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and Proxy Statements for the Company’s annual stockholders’ meetings, and other information statements as filed with the SEC. In addition, the Company provides a webcast of its quarterly earnings calls and certain events in which management participates or hosts with members of the investment community.Non-GAAP Financial TermsThis press release contains certain non-GAAP financial terms that include adjusted EBITDA. The Company defines adjusted EBITDA as Consolidated Operating Income before non-run-rate plus Depreciation and Amortization. “Non-run-rate” items are items that, while they may occur from period to period, are particularly material to results, impact costs primarily as a result of external market factors and may not occur in future periods if the same level of underlying performance were to occur. Forward-Looking StatementsThis press release contains statements which constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the beliefs and assumptions of management based on information available to it at the time such statements are made. Kaiser Aluminum cautions that any forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may vary materially from those in the forward-looking statements as a result of various factors. These factors include: (a) the satisfaction of the conditions to closing, including the receipt of regulatory approval; (b) the Company’s ability to integrate acquired operations and technologies, continue to realize manufacturing efficiencies and remain a low cost producer, drive innovative solutions and further advance its capabilities; (c) the effectiveness of management's strategies and decisions, including capital spending strategies and decisions; (d) general economic and business conditions, including the impact of the global outbreak of Coronavirus Disease 2019 and governmental and other actions taken in response, cyclicality and other conditions in the aerospace, defense, automotive, general engineering, aluminum packaging and other end markets the Company serves; and (e) other risk factors summarized in the Company's reports filed with the Securities and Exchange Commission, including the Company's Form 10-K for the year ended December 31, 2019 and Form 10-Qs for quarters ended March 31, 2020, June 30, 2020, and September 30, 2020. The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.Investor Relations and Public Relations Contact:Melinda C. Ellsworth Kaiser Aluminum Corporation (949) 614-1757
‘The good thing about a Biden run is that he would make Hillary look so much better,’ Neera Tanden said in 2015
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on November 30, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 76,200 shares of its common stock to ten new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Spero (or following a bona fide period of non-employment), as an inducement material to such individuals’ entering into employment with Spero, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.The options have an exercise price of $16.57 per share, which is equal to the closing price of Spero’s common stock on The Nasdaq Global Select Market on November 30, 2020. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36-months, subject to each employee’s continued employment with Spero on such vesting dates. The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of a stock option agreement covering the grant.About Spero Therapeutics Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections and rare diseases.Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.Spero is also advancing SPR720, its novel oral therapy product candidate being developed for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform that is being developed to treat MDR Gram-negative infections in the hospital setting.For more information, visit https://sperotherapeutics.com.Spero Investor and Media Contact: Sharon Klahre Vice President, Investor Relations 857-242-1547 IR@sperotherapeutics.com
FRANKLIN, Ind., Nov. 30, 2020 (GLOBE NEWSWIRE) -- IBC Advanced Alloys Corp. (“IBC” or the “Company”) (TSX-V: IB; OTCQB: IAALF) announces that, in accordance with the terms of a debenture indenture entered into between the Company and Computershare Trust Company of Canada (“Computershare”) dated June 6, 2018, as supplemented (the “Debenture Indenture”) and the terms of a convertible debenture indenture entered into between the Company and Computershare dated June 6, 2018, as supplemented (the “Convertible Debenture Indenture” and together with the Debenture Indenture, the “Indentures”), it has elected to issue common shares in the capital of the Company (“Common Shares”) to holders of 9.50% unsecured debentures due June 6, 2023 (the “9.50% Debentures”) and 8.25% convertible unsecured debentures due June 6, 2023 (the “8.25% Debentures” and together with the 9.50% Debentures, the “Debentures”), respectively, in satisfaction of up to an aggregate total of approximately C$153,830.84 interest payable to holders of Debentures on December 31, 2020 (the “Payment Date”), assuming no further conversions of 8.25% Debentures. Further to the short-form prospectus dated May 28, 2018 qualifying the distribution of the Debentures, the price of the Common Shares will be based on the volume-weighted average trading price per Common Share for the 20 consecutive trading days on the TSX Venture Exchange (the “TSXV”) ending on fifth day prior to the Payment Date, being the 20 consecutive trading days from November 27, 2020 to December 24, 2020, provided that such price is not less than the closing market price on December 24, 2020.The issuance of the Common Shares in lieu of cash is subject to the terms and conditions of the Indentures as well as the receipt of all requisite approvals, including, without limitation, the approval of the TSXV.For more information on IBC and its innovative alloy products, go here.On Behalf of the Board of Directors:"Mark Smith”Mark Smith, CEO & ChairmanContact:Mark A. Smith, CEO & Chairman Jim Sims, Director of Investor and Public Relations +1 (303) 503-6203 Email: email@example.comWebsite: www.ibcadvancedalloys.com@IBCAdvanced $IB $IAALF Beryllium BeralcastAbout IBC Advanced Alloys Corp.IBC is a leading beryllium and copper advanced alloys company serving a variety of industries such as defense, aerospace, automotive, telecommunications, precision manufacturing, and others. IBC's Copper Alloys Division manufactures and distributes a variety of copper alloys as castings and forgings, including beryllium copper, chrome copper, and aluminum bronze. IBC's Engineered Materials Division makes the Beralcast® family of alloys, which can be precision cast and are used in an increasing number of defense, aerospace, and other systems, including the F-35 Joint Strike Fighter. IBC's has production facilities in Indiana, Massachusetts, Pennsylvania, and Missouri. The Company's common shares are traded on the TSX Venture Exchange under the symbol "IB" and the OTCQB under the symbol "IAALF".Cautionary StatementsThe TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy of this news release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Certain information contained in this news release may be forward-looking information or forward-looking statements as defined under applicable securities laws. Forward-looking information and forward-looking statements are often, but not always identified by the use of words such as "expect", "anticipate", "believe", "foresee", "could", "estimate", "goal", "intend", "plan", "seek", "will", "may" and "should" and similar expressions or words suggesting future outcomes. This news release includes forward-looking information and statements pertaining to, among other things, the price of the Common Shares to be issued in lieu of cash. Forward-looking statements involve substantial known and unknown risks and uncertainties, certain of which are beyond the Company's control including: the impact of general economic conditions in the areas in which the Company or its customers operate, including the semiconductor manufacturing and oil and gas industries, risks associated with manufacturing activities, changes in laws and regulations including the adoption of new environmental laws and regulations and changes in how they are interpreted and enforced, increased competition, the lack of availability of qualified personnel or management, limited availability of raw materials, fluctuations in commodity prices, foreign exchange or interest rates, stock market volatility and obtaining required approvals of regulatory authorities. As a result of these risks and uncertainties, the Company's future results, performance or achievements could differ materially from those expressed in these forward-looking statements. All statements included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances.Please see “Risks Factors” in our Annual Information Form available under the Company’s profile at www.sedar.com, for information on the risks and uncertainties associated with our business. Readers should not place undue reliance on forward-looking information and statements, which speak only as of the date made. The forward-looking information and statements contained in this release represent our expectations as of the date of this release. We disclaim any intention or obligation or undertaking to update or revise any forward-looking information or statements whether as a result of new information, future events or otherwise, except as required under applicable securities laws.
West Ham live dangerously but Bowen's goal is enough to deny Aston Villa
Tehran [Iran], December 1 (ANI): Days after Iran's nuclear arms program scientist was assassinated, a senior commander in Iran's Revolutionary Guards has been killed in a drone strike near the Syria-Iraq border.
The campmates have been sharing more tales of meeting famous people.
Hilltop Securities Inc. (HilltopSecurities) recently welcomed Managing Director Ike Papadopoulos to the firm’s public finance division. Papadopoulos’ responsibilities will include expanding HilltopSecurities’ East Coast investment banking effort.
BlackRock will host a conference call on Wednesday, December 2nd at 2:00pm ET. The call will feature Tony Kim and Erin Xie, portfolio managers for BlackRock Science and Technology Trust II (BSTZ) and BlackRock Health Sciences Trust II (BMEZ), respectively.
Alcoa Corporation today announced an agreement to sell its rolling mill business, held by Alcoa Warrick LLC, to Kaiser Aluminum Corporation for total consideration of approximately $670 million, which includes $587 million in cash and the assumption of $83 million in other postretirement employee benefit (OPEB) liabilities.
Imperial announced today Theresa Redburn, Senior Vice-President, Commercial and Corporate Development has announced her intention to retire...
Thunderbird Entertainment Group Inc. (TSXV:TBRD, OTCQX: THBRF) (Thunderbird or the Company), today announced its financial results for the first quarter ended September 30, 2020 ("Fiscal 2021"), and provided a corporate update.
This notice provides stockholders of Tortoise Pipeline & Energy Fund, Inc. (NYSE: TTP) and Tortoise Power and Energy Infrastructure Fund, Inc. (NYSE: TPZ) with information regarding the distributions paid on November 30, 2020 and cumulative distributions paid fiscal year-to-date.